Prevention of coronary heart disease through cholesterol reduction

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Growing evidence suggests that lowering serum cholesterol levels, particularly low-density lipoprotein levels, will reduce the risk for coronary heart disease. The benefit of cholesterol-lowering therapy has been documented by many clinical trials. Two secondary prevention trials, the Scandinavian Simvastatin Survival Study and the Cholesterol and Recurrent Events trial, demonstrated a striking reduction in recurrent coronary heart disease without an increase in noncardiovascular mortality; treatment with simvastatin reduced total mortality by 30 percent. A primary prevention trial, the West of Scotland Coronary Prevention Study, demonstrated similar results in high-risk patients without established coronary heart disease. More recent angiographic trials revealed that cholesterol-lowering therapy will reduce progression of atherosclerosis and, in some cases, will reverse existing lesions. Use of HMG-CoA reductase inhibitors also appears to be beneficial and safe. Evidence supports cholesterol-lowering therapy in high- risk patients, both with and without established atherosclerotic disease.

Original languageEnglish (US)
Pages (from-to)2250-2258
Number of pages9
JournalAmerican Family Physician
Volume55
Issue number6
StatePublished - May 1 1997

Fingerprint

Coronary Disease
Cholesterol
Simvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mortality
Scotland
Primary Prevention
Therapeutics
Secondary Prevention
LDL Lipoproteins
Atherosclerosis
Clinical Trials
Survival
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prevention of coronary heart disease through cholesterol reduction. / Grundy, Scott M.

In: American Family Physician, Vol. 55, No. 6, 01.05.1997, p. 2250-2258.

Research output: Contribution to journalArticle

@article{27b8e5350fcc4bb4a34393b0bd4e87bb,
title = "Prevention of coronary heart disease through cholesterol reduction",
abstract = "Growing evidence suggests that lowering serum cholesterol levels, particularly low-density lipoprotein levels, will reduce the risk for coronary heart disease. The benefit of cholesterol-lowering therapy has been documented by many clinical trials. Two secondary prevention trials, the Scandinavian Simvastatin Survival Study and the Cholesterol and Recurrent Events trial, demonstrated a striking reduction in recurrent coronary heart disease without an increase in noncardiovascular mortality; treatment with simvastatin reduced total mortality by 30 percent. A primary prevention trial, the West of Scotland Coronary Prevention Study, demonstrated similar results in high-risk patients without established coronary heart disease. More recent angiographic trials revealed that cholesterol-lowering therapy will reduce progression of atherosclerosis and, in some cases, will reverse existing lesions. Use of HMG-CoA reductase inhibitors also appears to be beneficial and safe. Evidence supports cholesterol-lowering therapy in high- risk patients, both with and without established atherosclerotic disease.",
author = "Grundy, {Scott M}",
year = "1997",
month = "5",
day = "1",
language = "English (US)",
volume = "55",
pages = "2250--2258",
journal = "American Family Physician",
issn = "0002-838X",
publisher = "American Academy of Family Physicians",
number = "6",

}

TY - JOUR

T1 - Prevention of coronary heart disease through cholesterol reduction

AU - Grundy, Scott M

PY - 1997/5/1

Y1 - 1997/5/1

N2 - Growing evidence suggests that lowering serum cholesterol levels, particularly low-density lipoprotein levels, will reduce the risk for coronary heart disease. The benefit of cholesterol-lowering therapy has been documented by many clinical trials. Two secondary prevention trials, the Scandinavian Simvastatin Survival Study and the Cholesterol and Recurrent Events trial, demonstrated a striking reduction in recurrent coronary heart disease without an increase in noncardiovascular mortality; treatment with simvastatin reduced total mortality by 30 percent. A primary prevention trial, the West of Scotland Coronary Prevention Study, demonstrated similar results in high-risk patients without established coronary heart disease. More recent angiographic trials revealed that cholesterol-lowering therapy will reduce progression of atherosclerosis and, in some cases, will reverse existing lesions. Use of HMG-CoA reductase inhibitors also appears to be beneficial and safe. Evidence supports cholesterol-lowering therapy in high- risk patients, both with and without established atherosclerotic disease.

AB - Growing evidence suggests that lowering serum cholesterol levels, particularly low-density lipoprotein levels, will reduce the risk for coronary heart disease. The benefit of cholesterol-lowering therapy has been documented by many clinical trials. Two secondary prevention trials, the Scandinavian Simvastatin Survival Study and the Cholesterol and Recurrent Events trial, demonstrated a striking reduction in recurrent coronary heart disease without an increase in noncardiovascular mortality; treatment with simvastatin reduced total mortality by 30 percent. A primary prevention trial, the West of Scotland Coronary Prevention Study, demonstrated similar results in high-risk patients without established coronary heart disease. More recent angiographic trials revealed that cholesterol-lowering therapy will reduce progression of atherosclerosis and, in some cases, will reverse existing lesions. Use of HMG-CoA reductase inhibitors also appears to be beneficial and safe. Evidence supports cholesterol-lowering therapy in high- risk patients, both with and without established atherosclerotic disease.

UR - http://www.scopus.com/inward/record.url?scp=0031008218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031008218&partnerID=8YFLogxK

M3 - Article

C2 - 9149652

AN - SCOPUS:0031008218

VL - 55

SP - 2250

EP - 2258

JO - American Family Physician

JF - American Family Physician

SN - 0002-838X

IS - 6

ER -